Search
Close this search box.
Search

Category: Press Releases

Synchronoss Achieves EU-U.S. Data Privacy Framework Certification

Reinforcing Global Leadership in Data Protection, Compliance, and Consumer Trust BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), a global leader and innovator in personal cloud platforms for telecoms, today announced that it has achieved certification under the EU-U.S. Data Privacy Framework (DPF), administered by the U.S. Department of Commerce. The DPF is a transatlantic data transfer mechanism that enables U.S.-based organizations to receive and process personal data from the European Union in compliance with European privacy laws, such as the General Data Protection Regulation (GDPR). The framework provides robust safeguards, enforcement mechanisms, and redress

Synchronoss Achieves EU-U.S. Data Privacy Framework Certification

Reinforcing Global Leadership in Data Protection, Compliance, and Consumer Trust BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), a global leader and innovator in personal cloud platforms for telecoms, today announced that it has achieved certification under the EU-U.S. Data Privacy Framework (DPF), administered by the U.S. Department of Commerce. The DPF is a transatlantic data transfer mechanism that enables U.S.-based organizations to receive and process personal data from the European Union in compliance with European privacy laws, such as the General Data Protection Regulation (GDPR). The framework provides robust safeguards, enforcement mechanisms, and redress

Synchronoss Achieves EU-U.S. Data Privacy Framework Certification

Reinforcing Global Leadership in Data Protection, Compliance, and Consumer Trust BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), a global leader and innovator in personal cloud platforms for telecoms, today announced that it has achieved certification under the EU-U.S. Data Privacy Framework (DPF), administered by the U.S. Department of Commerce. The DPF is a transatlantic data transfer mechanism that enables U.S.-based organizations to receive and process personal data from the European Union in compliance with European privacy laws, such as the General Data Protection Regulation (GDPR). The framework provides robust safeguards, enforcement mechanisms, and redress

Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin

Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current […]

Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin

Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP), to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction (DDI) studies, to certify impurities are below the Acceptable Intake (AI) Limit set by U.S. Food and Drug Administration (FDA) guidelines.

Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin

Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP), to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction (DDI) studies, to certify impurities are below the Acceptable Intake (AI) Limit set by U.S. Food and Drug Administration (FDA) guidelines.